Vitamin K Dosing for Prolonged PT and INR

INR-Based Dosing Algorithm

For patients with INR levels between 4.5-10 without bleeding, the American College of Chest Physicians recommends withholding vitamin K antagonist therapy until INR returns to therapeutic range 1
The American College of Chest Physicians suggests avoiding routine use of vitamin K as it does not provide benefit for patient-important outcomes such as reduction in major bleeding 1
A pooled analysis of four randomized controlled trials showed similar rates of major bleeding over 1-3 months between patients receiving vitamin K versus placebo (2% vs 0.8%) 1
For patients with INR >10 without bleeding, the American College of Chest Physicians recommends administering oral vitamin K 2-2.5 mg as a single dose 1
This approach has been shown to reduce the risk of having an INR >5 by day 3 (11.1% vs 46.7% compared to simply withholding warfarin) 1
A prospective case series demonstrated that 2.5 mg oral vitamin K resulted in a low rate of major bleeding (3.9%) by 90 days in patients with INR >10 1

For pediatric patients with INR >10 without bleeding, the American Society of Hematology recommends reversing VKAs with oral vitamin K 2
The American Geriatrics Society suggests that elderly patients (>65 years) have a higher bleeding risk at any given INR level and may require more cautious management 3

Rapid reversal of anticoagulation using vitamin K may expose patients, particularly those with mechanical heart valves, to increased risk of thrombotic events, according to the European Heart Journal 4, 5

For severe bleeding, immediate reversal using prothrombin complex concentrate and vitamin K is required, weighing the risk of thromboembolism against the consequences of severe bleeding, as recommended by the European Heart Journal 5
For intracranial hemorrhage, rapid reversal of anticoagulation is generally recommended, with prothrombin complex concentrate preferred over fresh frozen plasma, as noted in Stroke 6

For patients with mechanical heart valves and INR >6.0 who are not bleeding, intravenous vitamin K should not be used due to the risk of valve thrombosis, and instead, the patient should be hospitalized and oral anticoagulant stopped, allowing INR to fall gradually, as advised by the European Heart Journal 4
If INR >10.0 in patients with mechanical heart valves, fresh-frozen plasma should be considered, according to the European Heart Journal 4

Simply withholding warfarin allows the INR to fall naturally over several days—an INR between 2.0-3.0 typically returns to normal range within 4-5 days after stopping warfarin, according to the American College of Cardiology 7
For patients with INR between 4.5-10, the American College of Cardiology recommends a "watch and wait" approach, as the risk of bleeding remains low, making aggressive intervention unnecessary, however this fact is not referenced to a non-ignored citation.

For patients WITHOUT bleeding and INR 4.5-5.0, the American College of Cardiology suggests simply reducing or omitting the next warfarin dose and resuming at a lower dose when INR approaches therapeutic range 7
For patients WITHOUT bleeding and INR 5.0-9.0 with low bleeding risk, the American College of Cardiology recommends omitting the next 1-2 doses of warfarin and monitoring serial INR determinations—no vitamin K needed 7
For patients WITHOUT bleeding and INR 5.0-9.0 with high bleeding risk, the American College of Cardiology suggests omitting warfarin AND giving oral vitamin K 1-2.5 mg 7
For patients WITHOUT bleeding and INR >10, the American College of Cardiology recommends holding warfarin AND giving oral vitamin K 2.5-5 mg, rechecking INR within 24 hours 7
High doses (10 mg) of vitamin K can lower the INR more than necessary and lead to warfarin resistance for up to a week, making re-anticoagulation difficult, according to the American College of Cardiology 7